

局部晚期鼻咽癌的综合治疗进展

何阳科 张幸平[△]

(重庆医科大学附属第一医院肿瘤科 重庆 400016)

摘要 :鼻咽癌在流行病学、生物学行为及治疗方法上与其他肿瘤不尽相同,对放疗及化疗均具有较高的敏感性。放疗及化疗等手段结合的综合治疗已成为鼻咽癌的治疗标准。早期患者预后较好,但局部晚期鼻咽癌因其具有较高的局部复发率及远处转移率而导致治疗效果欠佳。如何提高其治疗效果仍在进一步临床研究中。

关键词 :鼻咽癌;放射治疗;化疗;靶向治疗

中图分类号 R 739.63 文献标识码 A 文章编号 1673-6273(2012)05-972-03

Progress of Combined Modality Therapy in Locally Advanced Nasopharyngeal Carcinoma

HE Yang-ke, ZHANG Xing-ping[△]

(Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, 400016, Chongqing China)

ABSTRACT: There are many differences in epidemiology, biological behavior and treatment between nasopharyngeal carcinoma and other tumor. Nasopharyngeal carcinoma is highly responsive to both chemotherapy and radiotherapy. Radiotherapy combined with chemotherapy and other methods has become the standard treatment for nasopharyngeal carcinoma. Unlike early stage nasopharyngeal carcinoma, locally advanced nasopharyngeal carcinoma often has a poor prognosis because of higher local recurrence and distant metastases. How to improve the therapeutic effect is still under further clinical studies.

Key words: Nasopharyngeal carcinoma; Radiation therapy; Chemotherapy; Targeted therapy

Chinese Library Classification: R739.63 **Document code**: A

Article ID: 1673-6273(2012)05-972-03

鼻咽癌(nasopharyngeal carcinoma, NPC)是我国最常见的恶性肿瘤之一。由于其生物学行为特殊,早期病变的症状和体征常不明显,约70%的患者确诊时已属于局部晚期鼻咽癌(locally advanced nasopharyngeal carcinoma, LA-NPC)^[1,2],即2010年版AJCC临床分期中的Ⅲ期-Ⅳ期。对于LA-NPC公认的治疗手段是以放射治疗为主、化疗为辅的综合治疗,一些临床研究结果表明LA-NPC治疗后5年总生存率(overall survival, OS)为50%~60%^[3,4],但其较高的复发率及远处转移率导致治疗效果不理想。近年来新兴的分子靶向治疗为LA-NPC的综合治疗提供了新的思路。现将近年来国内外LA-NPC的综合治疗进展综述如下。

1 放射治疗是LA-NPC的主要治疗手段

由于鼻咽深在的解剖位置、复杂的周围结构及特殊的肿瘤组织学类型,目前国内外肿瘤界公认放射治疗是NPC主要的根治手段。在过去的四十年,常规放疗及二维适形放疗是NPC放疗的主要方式^[3,5]。Chen等^[6]用常规放疗技术治疗556例LA-NPC,鼻咽部照射总剂量为66 Gy~80 Gy/6.5周~8周,颈淋巴结引流区照射总剂量为60 Gy~70 Gy/6周~7周,5年OS为66.41%。由于常规放疗中,患者的颞叶下部、颞颌关节、腮腺、颌下腺等器官和组织不可避免地受到较高剂量的照射,使患者放疗后容易出现严重的口干症、张口受限、放射性脑脊髓

损伤等毒副反应,严重影响患者的生活质量^[6]。

随着放射治疗新技术的开展,尤其是调强适形放射治疗(intensity modulated radiation therapy, IMRT)及图像引导放射治疗(image guided radiation therapy, IGRT)等新技术的临床应用,精确放疗在鼻咽癌治疗中的优势越来越凸显出来。目前一些研究已证实IMRT治疗NPC显示出了较高的肿瘤控制率和患者生存率、较低的放疗副反应^[7-9]。

与常规放疗相比,IMRT通过对肿瘤靶体积处方剂量进行设定,对肿瘤周围的重要组织及器官剂量进行限定,使用物理补偿器、多叶准直器静态及动态调强等技术实现对射线剂量强度的调节,并通过计算机逆向计划设计使射线剂量分布高度适合靶区形状^[10]。IMRT在保证肿瘤区足够照射剂量的同时,可更好地保护周围敏感器官,减少腮腺、颞颌关节、脑、脊髓等正常组织所受照射体积及剂量,减少口干症、张口受限、放射性脑脊髓损伤等一系列放射相关毒副反应的发生率^[11]。韩露等^[12]总结了305例接受IMRT的鼻咽癌患者的资料,其中Ⅲ期168例,Ⅳa期92例。处方剂量为:肿瘤区(GTV)66.0 Gy~69.8 Gy,高危临床靶区(CTV-1)60 Gy~66.6 Gy,低危临床靶区(CTV-2)54.0 Gy~55.8 Gy,分割次数为30次~33次。结果提示Ⅲ期、Ⅳa期患者的3年无病生存率(disease-free survival, DFS)分别为81.1%和71.8%。急性毒副反应包括照射野内皮肤反应(Ⅰ度60.3%、Ⅱ度35.1%、Ⅲ度4.6%)、口腔黏膜反应(Ⅰ度19.4%、Ⅱ度51.1%、Ⅲ度29.5%)。在晚期毒副反应中,IMRT治疗后3月Ⅰ度、Ⅱ度口干症的发生率分别为5%和95%;治疗后3年Ⅰ度、Ⅱ度及Ⅲ度口干症分别为18.1%、78.4%及3.4%,未观

[△]通讯作者 张幸平,电话 023-89012672,

E-mail: zhang.xinping@163.com

(收稿日期:2011-09-07 接受日期:2011-09-30)

观察到Ⅰ度口干症。Chen等^[13]通过测量211例NPC患者IMRT治疗前后最大张口距离(maximal interincisal distance, MID)来观察患者放疗后张口受限的发生情况。所有患者治疗前的基础MID为45.5±5.5 mm,治疗后6月、1年、2年、3年、4年、5年所测量值与基础MID相比的标准化MID分别为94.6%±9.9%、92.5%±10.5%、92%±10.6%、92.2%±10.5%、92.1%±10.2%、90.3%±11.4%。12名患者(5.7%)被确诊为Ⅱ度张口受限,而未观察到Ⅲ度的张口受限。作者认为IMRT技术能减少放疗后张口受限的发生率。Kam等^[14]比较了56例NPC患者IMRT与常规放疗对腮腺功能的影响。作者随机地将56例患者平均分为IMRT组及普通放疗组,IMRT组可观察到的严重口干症发生率明显低于普通放疗组(9.3% VS 82.1% $P=0.01$)。

目前多数学者认为^[9,10,12]应用IMRT治疗LA-NPC,在获得较高局控率及生存率的同时,可明显地减少放疗毒副反应的发生率,提高患者的生活质量。

2 化疗在LA-NPC治疗中的作用

LA-NPC治疗失败的主要原因常为远处转移及局部复发,其中远处转移更为常见^[15]。目前较多学者^[16-19]主张对LA-NPC患者应用同步放化疗(concurrent chemoradiotherapy, CCRT),即在放疗的同时进行化疗。CCRT治疗LA-NPC的疗效要优于单纯放疗或放疗加辅助化疗,可降低肿瘤局部复发率及远处转移率,提高生存率。

Chan等^[20]将350例Ⅱ~Ⅲ期NPC患者随机分为每周一次低剂量顺铂(40 mg/m²/周)CCRT组和单纯放疗组。经中位随访时间为66个月随访后,CCRT组的OS较单纯放疗组高11%(70% VS 59% $P=0.065$)。国内外的荟萃分析证实了CCRT在LA-NPC治疗中的重要作用。Lanqendijk等^[21]总结了国外10项随机临床研究,包括2450例NPC患者。其中放疗配合化疗的患者(1226例)与单纯放疗的患者(1224例)相比,死亡危险比(HR)为0.82(95%CI 0.71~0.95 $P=0.01$)。作者进一步将这10项研究中以加入化疗的顺序分为三大类:新辅助化疗、同步放化疗及辅助化疗,分别与单纯放疗进行比较,发现CCRT的3年OS提高了20%,死亡HR为0.48(95%CI 0.32~0.72, $P=0.02$)。作者认为CCRT对提高患者OS更有优势。Zhang等^[22]对7项随机研究进行了荟萃分析,结果发现在2年、3年及5年OS方面,CCRT与单纯放疗相比有较高的生存获益,其风险比(RR)分别为0.63(95%CI 0.50~0.80 $P=0.0002$)、0.76(95%CI 0.61~0.93 $P=0.010$)、0.74(95%CI 0.62~0.89 $P=0.001$)。Baujat等^[23]所做的荟萃分析认为CCRT与单纯放疗比较5年OS提高了6%(62% VS 56%),死亡HR为0.82(95%CI 0.71~0.94 $P=0.006$)。杨安奎等^[24]对国内18项关于CCRT与单纯放疗在LA-NPC中应用的比较研究进行荟萃分析。结果表明,CCRT组比单纯放疗组的3年、5年OS分别提高了12%(68.47% VS 56.38% $P<0.0001$)和11%(51.91% VS 41.09%, $P<0.0001$),远处转移率减少了12%(26.19% VS 38.71% $P<0.0001$)。

CCRT可提高肿瘤治疗效果的作用机制可能为:(1)放射线及化疗药物直接杀灭原发肿瘤及微小转移灶;(2)CCRT后

使处于不同细胞周期的肿瘤细胞同步化,细胞阻滞于G2/M期,对放疗更敏感;(3)化疗药物通过抑制肿瘤细胞的亚致死性放射损伤的修复来增强放疗的作用,以达到协同增敏的目的;(4)CCRT避免了放射治疗时间的延迟^[14]。

CCRT在提高患者生存率的同时也增加了急性毒副反应发生率。Lin等^[25]的Ⅱ期临床研究报道,284例患者随机分为两组,两组均采用相同的放疗方案。实验组在放疗的第1、5周分别予以顺铂20 mg/m²/d及氟尿嘧啶400 mg/m²/d,4天(96小时)持续静脉滴注,对照组仅行放射治疗。通过65个月的随访,结果显示CCRT组患者3年OS明显提高(72.3% VS 54.2%, $P=0.0022$)。但CCRT组患者的急性毒副反应较单纯放疗组明显增加,以白细胞减少(0度36.9% VS 60.8%、Ⅰ度58.9% VS 39.2%、Ⅱ度4.3% VS 0%, $P<0.05$)及呕吐(0度46.1% VS 95.1%、Ⅰ度49.6% VS 4.9%、Ⅱ度4.3% VS 0%, $P<0.05$)尤为明显。

与单纯放疗相比,CCRT能提高LA-NPC患者的OS。但LA-NPC患者通过CCRT在获得较好治疗效果的同时,也会增加血液系统毒性、呕吐、口腔黏膜炎等并发症发生率的风险。

3 LA-NPC的分子靶向治疗

肿瘤分子靶向治疗(molecular targeted therapy)是近年来新兴的治疗手段。随着表皮生长因子受体(epidermal growth factor receptor, EGFR)及其信号传导机制的发现,EGFR的信号传导通路被认为与肿瘤细胞的增殖、转移和放射敏感性密切相关。目前EGFR拮抗剂主要有:EGFR单克隆抗体(如:西妥昔单抗、尼妥珠单抗等)及小分子酪氨酸激酶抑制剂(如:吉非替尼、索拉非尼等)。已有文献报道NPC高表达EGFR^[26],适合行抗EGFR的分子靶向治疗。

Bonner等^[27]将424例局部晚期头颈部癌患者随机分为西妥昔单抗联合放疗组(211例)及单纯放疗组(213例),结果发现联合组患者的中位生存时间较单纯放疗组长(49月 VS 29.3月, HR 0.74, 95%CI 0.57~0.97, $P=0.03$)。作者认为西妥昔单抗联合放疗可延长患者生存时间。Suntharalingam等^[28]报道43例LA-NPC患者接受西妥昔单抗联合TP方案化疗及放疗的Ⅱ期临床研究。其中3年OS及3年DFS分别为59%及58%,3年局控率为72%。Ⅲ度以上的毒副反应发生率分别为:黏膜炎79%、皮疹9%、白细胞减少19%、放射性皮炎16%。有26%的患者因毒副反应太重而暂停放疗。作者认为西妥昔单抗联合化疗及放疗使急性毒副反应增加。Rodríguez等^[29]报道的一项关于尼妥珠单抗的实验研究,共纳入106例晚期头颈部鳞癌患者,分为实验组(尼妥珠单抗联合放化疗)及对照组(安慰剂联合放化疗)。结果表明,实验组较对照组有更多患者达到完全缓解(59.5% VS 34.2%, $P=0.028$)。另外,一些吉非替尼、索拉非尼等药物的Ⅱ期临床研究也提示分子靶向治疗在LA-NPC的综合治疗中有着较令人满意的疗效^[29,30]。

4 展望

精确放疗是LA-NPC的主要治疗手段。但LA-NPC单纯放疗疗效不佳,其主要原因为肿瘤远处转移及局部复发。放化疗综合治疗LA-NPC有助于提高肿瘤局控率及患者生存率目前

已逐步成为共识(1类证据),分子靶向治疗为提高 LA-NPC 的疗效提供了可能性。然而放疗联合分子靶向药物的综合治疗仍有许多需要解决的问题,如何改善放疗、化疗及分子靶向综合治疗增加患者皮肤、黏膜及血液系统的毒副反应是今后亟待研究解决的课题。

参考文献(References)

- [1] Oksuz DC, Prestwich RJ, Carey B, et al. Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy [J]. *Radiat Oncol* 2011, 6:54
- [2] Dechaphunkul T, Pruegsanusak K, Sangthawan D, et al. Concurrent chemoradiotherapy with carboplatin followed by carboplatin and 5-fluorouracil in locally advanced nasopharyngeal carcinoma [J]. *Head Neck Oncol*, 2011, 3:30
- [3] Lin JC, Jan JS, Hsu CY, et al. Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival [J]. *J Clin Oncol*, 2003, 21: 631-637
- [4] Kwong DL, Sham JS, Au GK, et al. Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study [J]. *J Clin Oncol*, 2004, 22: 2643-2653
- [5] Chen CY, Han F, Zhao C, et al. Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone [J]. *Br J Radiol*, 2009, 82:452-458
- [6] Yeh SA, Tang Y, Lui CC, et al. Treatment outcomes and late complications of 849 patients with nasopharyngeal carcinoma treated with radiotherapy alone [J]. *Int J Radiat Oncol Biol Phys*, 2005, 62: 672-679
- [7] Lee NY, Le QT. New developments in radiation therapy for head and neck cancer: intensity-modulated radiation therapy and hypoxia targeting [J]. *Semin Oncol*, 2008, 35:236-250
- [8] Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? [J]. *Int J Radiat Oncol Biol Phys*, 2011,80:661-668
- [9] Kam MK, Teo PM, Chau RM, et al. Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: the Hong Kong experience [J]. *Int J Radiat Oncol Biol Phys*, 2004, 60:1440-1450
- [10] Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls [J]. *J Clin Oncol*, 2006, 24:2618-2623
- [11] 殷蔚伯. 肿瘤放射治疗学[M]. 4版. 中国协和医科大学出版社
Yin Wei-bo. *Radiation Therapy Oncology* [M]. 4th Edition. China Union Medical University Press
- [12] Han L, Lin SJ, Pan JJ, et al. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy [J]. *Chin J Cancer*, 2010, 29:145-150
- [13] Chen YY, Zhao C, Wang J, et al. Intensity-modulated radiation therapy reduces radiation-induced trismus in patients with nasopharyngeal carcinoma: a prospective study with >5 years of follow-up [J]. *Cancer*, 2011, 117: 2910-2916
- [14] Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients [J]. *J Clin Oncol*, 2007, 25: 4873-4879
- [15] Ng WT, Lee MC, Hung WM, et al. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma [J]. *Int J Radiat Oncol Biol Phys*, 2011, 79: 420-428
- [16] Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099 [J]. *J Clin Oncol*, 1998, 16: 1310-1317
- [17] Ma BB, Chan AT. Recent perspectives in the role of chemotherapy in the management of advanced nasopharyngeal carcinoma [J]. *Cancer*, 2005, 103:22-31
- [18] Wong FC, Ng AW, Lee VH, et al. Whole-field simultaneous integrated-boost intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma [J]. *Int J Radiat Oncol Biol Phys*, 2010, 76:138-145
- [19] Kim K, Wu HG, Kim HJ, et al. Intensity-modulated radiation therapy with simultaneous integrated boost technique following neoadjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma [J]. *Head Neck*, 2009, 31:1121-1128
- [20] Chan AT, Leung SF, Ngan RK, et al. Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma [J]. *J Natl Cancer Inst*, 2005, 97: 536-539
- [21] Langendijk JA, Leemans CR, Buter J, et al. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature [J]. *J Clin Oncol*, 2004, 22: 4604-4612
- [22] Zhang L, Zhao C, Ghimire B, et al. The role of concurrent chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma among endemic population: a meta-analysis of the phase III randomized trials [J]. *BMC Cancer*, 2010, 10:558
- [23] Baujat B, Audry H, Bourhis J, et al. Chemotherapy in locally advanced nasopharyngeal carcinoma: an individual patient data meta-analysis of eight randomized trials and 1753 patients [J]. *Int J Radiat Oncol Biol Phys*, 2006, 64:47-56
- [24] 杨安奎,刘天润,郭翔等. 同步放化疗与单纯放疗在晚期鼻咽癌中疗效比较的 Meta 分析 [J]. *中华耳鼻咽喉头颈外科杂志*, 2008, 43 (3): 216-23
Yan gan-Kui, Liu Tian-run, Guo Xiang, et al. Concurrent chemoradiotherapy versus radiotherapy alone for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis [J]. *Chinese journal of otorhinolaryngology head and neck surgery*, 2008, 43(3): 216-223
- [25] Agulnik M, Epstein JB. Nasopharyngeal carcinoma: current management, future directions and dental implications [J]. *Oral Oncol*, 2008, 44: 617-627
- [26] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck [J]. *N Engl J Med*, 2006,354: 567-578
- [27] Suntharalingam M, Kwok Y, Goloubeva O, et al. Phase II Study Evaluating the Addition of Cetuximab to the Concurrent Delivery of Weekly Carboplatin, Paclitaxel, and Daily Radiotherapy for Patients With Locally Advanced Squamous Cell Carcinomas of the Head and Neck [J]. *Int J Radiat Oncol Biol Phys*, 2011. 2011 May 19. [Epub ahead of print]

(下转第 1000 页)

- [7] Mun Kyung Hwang, Nu Ry Song, Nam Joo Kang, et al. Activation of phosphatidylinositol 3-kinase is required for tumor necrosis factor- α -induced upregulation of matrix metalloproteinase-9 its direct inhibition by quercetin[J]. J Biochemistry & cell biology, 2009, 41(7): 1592-1600
- [8] Gan X, Wong B, Wright SD, et al. Production of matrix metalloproteinase-9 in CaCO-2 cells in response to inflammatory stimuli [J]. J Interferon Cytokine Res, 2001, 21(2): 93-98
- [9] Martin J, Yung S, Robson RL. Production and regulation of matrix metalloproteinases and their inhibitors by human peritoneal mesothelial cells[J]. Perit Dial Int, 2000, 20(5): 524-533
- [10] Wei Li, Han Li, Alan D Bocking, et al. Tumor necrosis factor stimulates matrix metalloproteinase 9 secretion from cultured human chorionic trophoblast cells through tnfr receptor 1 signaling to IKB-KB-NFKB and MAPK1/3 pathway [J]. Biol Reprod, 2010, 83(3): 481-487
- [11] Yung-Chen Chou, Joen-Rong Sheu, Chi-Li Chung et al. Nuclear-targeted inhibition of nf-kbon MMP-9 production by N-2-(4-bromophenyl) ethyl caffeamide in human monocytic cells [J]. Chem Biol Interact, 2010, 184(3):403-412
- [12] Siye Wang, Trong Le, Junji Chida, et al. Mechanisms of matrix metalloproteinase-9 upregulation and tissue destruction in various organs in influenza A virus infection [J]. J Med Invest. 2010, 57(1-2): 26-34
- [13] Uwe Schonbeck, Francois Mach, Peter Libby. Generation of biologically active IL-1 β by matrix metalloproteinases: A novel caspase-1-independent pathway of IL-1 β processing [J]. J Immunol, 1998, 161(7): 3340-3346
- [14] Philippe E, Van den Steen, Paul Proost, et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-IV, PF-4, and GRO- α and RANTES and MCP-2 intact [J]. Blood, 2000, 96(8): 2673-2681
- [15] 余旻, 李冠兰, 刘先哲等. 基质金属蛋白酶-9在多器官功能障碍综合征中的变化[J]. 中华急诊医学杂志 2009, 18(2): 165-169
- Yu Min, Li Guan-lan, Liu Xian-zhe, et al. Change of matrix metalloproteinase-9 in rats with multiple organ dysfunction syndrome [J]. Emerg Med, 2009, 18(2): 165-169
- [16] 滕林, 余旻, 李俊明, 等. MODS大鼠肺组织 TM 和 MMP-9 的表达 [J]. 中华急诊医学杂志 2009, 18(10): 1031-1036
- Teng Lin, Yu Min, Li Jun-ming, et al. Expression of thrombomodulin (TM) and matrix metalloproteinase-9 (MMP-9) in the lung of rats with multiple organ dysfunction syndrome [J]. Emerg Med, 2009, 18(10): 1031-1036
- [17] 余旻, 刘先哲, 邓群, 等. 血栓调节蛋白和基质金属蛋白酶在脓毒症及多器官功能障碍综合征中的意义 [J]. 中华急诊医学杂志, 2006, 15(6): 558-561
- Yu Min, Liu Xian-zhe, Deng Qun, et al. Significance of thrombomodulin and matrix metalloproteinase-9 in sepsis and multiple organ dysfunction syndrome [J]. Emerg Med, 2006, 15(6): 1031-1036
- [18] Timothy A. Sutton, K. J. Kelly, Henry E. Mang, et al. Minocycline reduces renal microvascular leakage in a rat model of ischemic renal injury [J]. Am J Physiol Renal Physiol, 2005, 288(1): 91-97
- [19] Ihtiyar E, Yasar NF, Erkasap N, et al. Effects of Doxycycline on Renal Ischemia Reperfusion Injury Induced by Abdominal Compartment Syndrome [J]. Surg Res, 2011, 167(1): 113-120
- [20] Haiwei Wu, Guohua Dong, Hua Jing, et al. Erythropoietin attenuates ischemia-reperfusion induced lung injury by inhibiting tumor necrosis factor- α and matrix metalloproteinase-9 expression [J]. European Journal of Pharmacology, 2009, 602(2-3): 406-412
- [21] Elzbieta Kolaczowska, Magdalena Chadzinska, Anna Scisłowska-Czarnecka, et al. Gelatinase B/matrix metalloproteinase-9 contributes to cellular infiltration in a murine model of zymosan peritonitis [J]. Immunobiology, 2006, 211(3): 137-148
- [22] Christoph A. Reichel, Markus Rehberg, Peter Bihari et al. Gelatinases mediate neutrophil recruitment in vivo: evidence for stimulus specificity and a critical role in collagen IV remodeling [J]. J Leukoc Biol, 2008, 83(4): 864-874

(上接第 974 页)

- [28] Rodriguez MO, Rivero TC, del Castillo Bahi R, et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck [J]. Cancer Biol Ther, 2010, 9: 343-349
- [29] Chan AT, Ma BB, Hui EP, et al. Phase II study of gefitinib in metastatic or locoregionally recurrent nasopharyngeal carcinoma (NPC) [C]. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings, 2006
- [30] Chen E, Winkquist E, Agulnik M. A phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC) [J]. Eur J Cancer supplement, 2005, 3(2): 297-305